16 results about "Post menopausal osteoporosis" patented technology

The invention relates to the field of disease animal model construction, and particularly discloses a postmenopausal osteoporosis and knee osteoarthritis co-disease animal model construction method which comprises the following steps: selecting a female animal as an experimental subject; the selected female animals are injected with a GnRH agonist, meanwhile, low-calcium feed feeding and oxidative stress stimulation are conducted, and feeding is conducted for a preset time; detecting bone mineral density and bone trabecula parameters of the fed female animals, and screening qualified female animals meeting set standards; performing meniscus tearing operation on the qualified female animal, and implanting sustained release microspheres loaded with inflammatory factors at the torn part during the operation; carrying out weight-bearing training on the female animal after the operation, and continuing for a set time length; and performing health detection on the female animals at different time points. According to the method, through multi-factor collaborative induction of the PMOP, minimally invasive construction of the KOA and multi-dimensional health detection, accurate simulation of a co-disease pathological process and clinical characteristics is realized, and the authenticity and stability of the model are improved.

The invention discloses a telmisartan glucoside derivative, a microbial conversion preparation method thereof and application of the telmisartan glucoside derivative in preparation of a medicine for preventing or treating osteoporosis. The telmisartan glucoside derivative is characterized in that a telmisartan propyl side chain is connected with a glucosyl group. According to the invention, a microbial conversion technology is utilized, telmisartan is taken as a substrate, and glucosyl is introduced into a telmisartan propyl side chain in a regioselective manner, so that the telmisartan glucoside derivative with a novel structure is obtained. Experiments on the osteoblast proliferation promoting activity and the postmenopausal osteoporosis resisting effect of the telmisartan glucoside derivative by using an in-vitro osteoblast model and an ovariectomized induced osteoporosis mouse model prove that the telmisartan glucoside derivative has relatively good osteoblast proliferation promoting activity and postmenopausal osteoporosis resisting activity; the compound can be used as an active component of a medicine for treating osteoporosis, and has wide application.

The present application relates to the technical field of medicine, and more particularly to the application of beta-hydroxybutyric acid in the preparation of a drug for preventing and / or treating osteoporosis, including postmenopausal osteoporosis due to estrogen deficiency and diabetic osteoporosis, wherein the concentration of the beta-hydroxybutyric acid is 150 mM, the application of beta-hydroxybutyric acid in the preparation of a drug for inhibiting the differentiation of osteoclasts or inhibiting the formation of osteoclasts, wherein the beta-hydroxybutyric acid inhibits the differentiation of osteoclast precursor cells into osteoclasts, and the concentration of the beta-hydroxybutyric acid is 10 mM; the present application proves that beta-hydroxybutyric acid improves the bone microstructure of OVX mice and db / db mice, inhibits the differentiation of osteoclasts, and reduces bone resorption, thereby providing a new target for the prevention and treatment of osteoporosis.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

The invention discloses a compound traditional Chinese medicine preparation for treating postmenopausal osteoporosis, osteoarthritis and / or premature ovarian insufficiency as well as a preparation method and application of the compound traditional Chinese medicine preparation, and belongs to the technical field of traditional Chinese medicines. The compound traditional Chinese medicine preparation is prepared from the following components: 10 to 30 g of radix rehmanniae preparata, 10 to 30 g of radix angelicae sinensis, 8 to 15 g of rhizoma chuanxiong, 8 to 15 g of radix paeoniae alba, 10 to 30 g of radix codonopsis, 8 to 15 g of rhizoma atractylodis macrocephalae, 10 to 30 g of poria cocos, 5 to 10 g of liquorice root, 10 to 30 g of radix dipsaci, 8 to 15 g of radix achyranthis bidentatae, 8 to 15 g of fructus chaenomelis lagenariae, the compound traditional Chinese medicine preparation provided by the invention realizes effective treatment on osteoporosis, osteoarthritis and early-onset ovarian insufficiency, overcomes various defects of an existing treatment method, remarkably improves the treatment effect, reduces the side effects of medicines, and brings a new treatment choice for patients. And a new thought and a new method are expected to be provided for solving the treatment problem of the three diseases.

The invention discloses an application of a polypeptide as a marker in diagnosis of postmenopausal osteoporosis. The polypeptide is selected from at least one of peptide fragments P2 to P4. Wherein the peptide fragment P2 has an amino acid sequence as shown in SEQ ID NO. 6; the peptide fragment P3 has an amino acid sequence as shown in SEQ ID NO.7; and the peptide fragment P4 has an amino acid sequence as shown in SEQ ID NO.8. Peptide fragments specifically recognized by OP patient serum IgG are screened and identified on the basis of a phage immunoprecipitation sequencing technology, so that peptide fragments P2-P4 are obtained, and it is verified that the peptide fragments P2-P4 can serve as markers to diagnose osteoporosis. It is further verified that the AUC value of the peptide fragment P2 and the peptide fragment P4 for combined diagnosis of osteoporosis can reach 0.920, the AUC value of the peptide fragment P2 and the peptide fragment P4 for combined diagnosis of postmenopausal osteoporosis can reach 0.958, and the peptide fragment P2 and the peptide fragment P4 have very high diagnosis efficacy.

The invention discloses a bone-targeted functionalized tetrahedral framework nucleic acid nano system as well as a preparation method and application thereof, the bone-targeted functionalized tetrahedral framework nucleic acid nano system comprises tetrahedral framework nucleic acid tFNA-Sa, polypeptide SDSSD with bone cell specific targeting and an osteoporosis treatment drug, the bone targeting tetrahedral framework nucleic acid tFNA-Sa is used for modifying bone targeting polypeptide to obtain the bone targeting tetrahedral framework nucleic acid tFNAs-SDSSD, the editability and the biocompatibility of the nucleic acid tetrahedron are utilized, the SDSSD bone targeting peptide is modified on the surface of the tetrahedron, the bone targeting ability can be given to the bone targeting peptide, and then the purposes of efficient aggregation of the medicine in bone tissue, high-efficiency drug delivery and the like are achieved. The distribution of the medicine in non-target tissues is reduced. The targeted delivery system not only can improve the treatment effect of the medicine, but also can greatly reduce the side effect of the medicine, and brings a new scheme for targeted therapy for postmenopausal osteoporosis.

This invention provides an application of the PDK4 gene, which is used to prepare drugs to improve postmenopausal osteoporosis. PDK4 gene deletion in bone marrow mesenchymal stem cells (BMSCs) reduces their osteogenic differentiation capacity and inhibits mitochondrial division by blocking the E2-DRP1 signaling axis. Overexpression in bone tissue reverses bone formation inhibition caused by postmenopausal osteoporosis. This invention redefines the biological function of the PDK4 gene in the skeletal system. This gene promotes osteogenic differentiation of BMSCs through the E2-ERα-PDK4-MYH9-DRP1 signaling axis, thus improving postmenopausal osteoporosis and providing a new theoretical framework and potential target for developing bone-promoting therapies for postmenopausal osteoporosis.

The invention discloses a preparation method and application of soybean-sourced nano phytoestrogen nano vesicles, belongs to the technical field of biological nano materials, solves the technical problems of poor bone targeting ability and low bioavailability of supplemented exogenous estrogens, and comprises the following steps: S1, weighing, cleaning and soaking; s2, crushing and filtering; s3, performing differential centrifugation; s4, performing extrusion to obtain nano phytoestrogen nano vesicles (SVs) from soybeans, and storing the nano phytoestrogen nano vesicles (SVs) at-80 DEG C for later use; the prepared SVs are applied to preparation of medicines for treating postmenopausal osteoporosis diseases. The soybean-sourced phytoestrogen nano-vesicle prepared by combining a differential centrifugation method with an extrusion method is wide in raw material source and simple in extraction process, is used as a plant estrogen, is rich in various bioactive components such as proteins, lipids and isoflavonoids, reverses the state of bone resorption and bone formation imbalance under the estrogen deficiency state, and has a good application prospect. And a new solution is provided for the treatment of postmenopausal osteoporosis.

The invention relates to the technical field of pharmaceutical preparations, in particular to a pharmaceutical composition for treating osteoporosis, a preparation and a preparation method and application thereof. The medicine composition is prepared from the following medicinal materials in parts by weight: 5 to 10 parts of herba epimedii, 10 to 15 parts of tortoise plastron, 6 to 12 parts of rhizoma anemarrhenae, 10 to 15 parts of radix rehmanniae recen, 10 to 15 parts of radix astragali, 6 to 12 parts of herba dendrobii, 6 to 12 parts of radix curcumae, 6 to 12 parts of rhizoma cyperi, 10 to 15 parts of semen cuscutae, 3 to 8 parts of colla corii asini, 10 to 15 parts of caulis spatholobi, 6 to 12 parts of cortex phellodendri, 10 to 15 parts of rhizoma drynariae and 10 to 15 parts of radix dipsaci. According to the present invention, the pathogenesis of the postmenopausal osteoporosis is deeply analyzed, the corresponding treatment method and the corresponding treatment rule are formulated according to the pathogenesis, the unique compatibility relationship between the compositions is finally formed, and the new osteoporosis treatment pharmaceutical composition is provided, is the pure traditional Chinese medicine preparation, has characteristics of no significant toxic-side effect, no side effect, no toxic-side effect, and no side effect, and can be used for treating the postmenopausal osteoporosis. Animal experiments prove that the traditional Chinese medicine preparation has a remarkable curative effect on postmenopausal osteoporosis.

The invention belongs to the technical field of medicine research and development, and provides application of edaravone in preparation of a medicine for treating postmenopausal osteoporosis aiming at the technical problem that whether edaravone has a treatment effect on postmenopausal osteoporosis or not is not reported at present. In addition, by constructing a mouse ovariectomized model and combining with a ferroptosis-induced osteogenesis / osteoclast system, the edaravone is proved to be capable of effectively increasing calcium salt deposition and mineralization after osteoporosis, improving poor osteogenesis of osteoblasts and osteoblast inflammatory response caused by osteoporosis, effectively improving FSP1 expression and improving osteoporosis. And meanwhile, the expression of 5-LOX and ACSL4 proteins is reduced, and the intraosseous ferroptosis microenvironment of the postmenopausal osteoporosis is regulated through ways of inhibiting ROS, inhibiting lipid peroxidation and the like, so that the treatment effect of relieving the progress of the postmenopausal osteoporosis is achieved.

The invention belongs to the technical field of fracture prediction, and discloses a postmenopausal woman vertebral osteoporotic fracture prediction model establishment method. Comprises: obtaining a training queue; performing univariate logistic regression analysis on the training queue, and screening out important high-risk factors related to an imminent fracture; performing minimum absolute shrinkage and selection operator regression on the training queue, and screening out key prediction factors from the important high-risk factors; and combining the key prediction factors into a logistic regression model, performing fitting based on the training queue, determining a coefficient of the logistic regression model, and obtaining a fracture prediction model. And the risk that a woman with postmenopausal osteoporosis is about to have OVCF can be predicted.

The present application relates to a kind of protein markers for diagnosing postmenopausal osteoporosis and its application, belong to biological medicine technical field.The present application is screened, and it is found that NADH dehydrogenase 1 beta subcomplex subunit 4, NADH dehydrogenase 1 beta subcomplex subunit 5, NADH dehydrogenase 1 beta subcomplex subunit 6, NADH dehydrogenase 1, NADH dehydrogenase 1 alpha subcomplex subunit 8, cytochrome c oxidase subunit 7C, cytochrome c oxidase subunit 5A and cytochrome c oxidase subunit 7A2 can be used alone or in combination in the diagnosis test of postmenopausal osteoporosis, to accurately evaluate the PMOP state of subject.Further, the combination of NDUB5 and NDUA8 two protein markers shows excellent diagnostic sensitivity and specificity, which is helpful for early diagnosis of PMOP, screening of high-risk population of fracture and precise prevention and treatment.

The invention relates to a protein marker for diagnosing postmenopausal osteoporosis and application thereof, and belongs to the technical field of biological medicine. Through screening, an NADH dehydrogenase 1 beta sub-complex subunit 4, an NADH dehydrogenase 1 beta sub-complex subunit 5, an NADH dehydrogenase 1 beta sub-complex subunit 6, an NADH dehydrogenase 1, an NADH dehydrogenase 1 alpha sub-complex subunit 8, a cytochrome c oxidase subunit 7C, a cytochrome c oxidase subunit 5A and a cytochrome c oxidase subunit 7A2 are found. The kit can be used in a diagnostic test of postmenopausal osteoporosis independently or in a combined manner, so as to accurately evaluate the PMOP state of a subject. Furthermore, the combination of the two protein markers NDUB5 and NDUA8 shows excellent diagnosis sensitivity and specificity, and is beneficial to early diagnosis of PMOP and screening and precise prevention and treatment of high-risk groups of fracture.

The present application relates to the application of 5-amino pentanamide in the preparation of osteoporosis diagnostic products, belonging to the field of biotechnology. Non-targeted metabolomics analysis is carried out on the plasma exosomes of 100 postmenopausal osteoporosis patients (case group) and 100 healthy controls (control group), and further variable screening of differential metabolites is carried out by LASSO regression, and it is found that the regression coefficient absolute value of 5-amino pentanamide (5-Aminopentanamide) is the largest, which is the most critical metabolite for distinguishing the case group from the control group. The content of 5-amino pentanamide in the case group is significantly lower than that in the control group, and the area under the curve (AUC) is 0.903, which has good prediction effect. The diagnostic marker of the present application significantly improves the accuracy and specificity of postmenopausal osteoporosis diagnosis.

This invention discloses the use of donkey-hide gelatin in the preparation of products for treating postmenopausal osteoporosis, belonging to the field of new pharmaceutical applications of donkey-hide gelatin. The use of donkey-hide gelatin in the preparation of products for treating postmenopausal osteoporosis utilizes a mechanism of action that regulates immune cells to mediate bone immune balance, thus treating osteoporosis. This invention reveals for the first time a novel mechanism by which donkey-hide gelatin regulates immune cells to mediate bone immune balance. This mechanism endows traditional donkey-hide gelatin with entirely new pharmaceutical value, exceeding expectations based on its traditional description as "strengthening muscles and bones." It indicates that donkey-hide gelatin can be used to prepare drugs or health products for treating postmenopausal osteoporosis, and is particularly suitable for the development of anti-osteoporosis preparations based on immune modulation mechanisms.